When should telomere length testing be ordered and how should confirmed short‑telomere results be managed?

When to Order Telomere Length Testing and Management of Short Telomeres

Telomere length testing should be ordered for patients with familial pulmonary fibrosis, suspected short telomere syndromes (dyskeratosis congenita, Hermansky-Pudlak syndrome), multisystem manifestations (pulmonary fibrosis with liver disease, bone marrow failure, or premature graying), young-onset pulmonary fibrosis (<50 years), or when evaluating pathogenicity of telomere gene variants. 1

Clinical Scenarios Warranting Telomere Length Testing

High-Yield Testing Scenarios

• Familial pulmonary fibrosis: Panel-based gene sequencing with telomere length (TL) testing should be considered for all patients with family history of pulmonary fibrosis, as up to 30% will harbor pathogenic variants 1

• Syndromic presentations: Test when clinical features suggest:

  • Dyskeratosis congenita: Nail dystrophy, reticular skin pigmentation, oral leukoplakia, bone marrow failure 1
  • Hermansky-Pudlak syndrome: Oculocutaneous albinism with bleeding diathesis 1
  • Young age at onset (adults <50 years or pediatric patients) 1

• Multisystem telomeropathy features: Coexistent pulmonary fibrosis with liver disease, bone marrow failure, myelodysplastic syndrome, acute myeloid leukemia, or premature hair graying 1

Testing Approach Algorithm

Flow-FISH (flow cytometry with fluorescence in situ hybridization) is the gold standard for clinical TL measurement 1, 2, providing both absolute length in kilobases and age-adjusted percentiles displayed on telograms.

Interpretation thresholds:

• TL >50th percentile: Short telomere syndrome unlikely; 100% negative predictive value for clinically relevant mutations 1, 2
• TL <10th percentile: Warrants further evaluation 3
• TL <1st percentile: Highly suggestive of short telomere syndrome even without identified mutation 1

Management of Confirmed Short Telomeres

Immediate Clinical Actions

When short TL is confirmed (<10th percentile), implement the following management changes 3:

1. Modify immunosuppression strategy: Reduce or avoid immunosuppressive therapy, as pathogenic variants in telomere genes (TERT, TERC, PARN, RTEL1) convey high risk for rapid progression regardless of specific diagnosis 1

2. Defer invasive procedures: Consider avoiding surgical lung biopsy since histopathologic analysis may be less prognostically informative 1

3. Accelerate transplant evaluation: Early referral to lung transplant centers is warranted given poor survival prognosis 1

4. Initiate appropriate antifibrotic therapy: Begin disease-modifying treatment promptly 1

Genetic Counseling and Family Testing

Offer genetic counseling with panel-based gene sequencing focusing on telomere maintenance genes (TERT, TERC, RTEL1, PARN, and others) 1. When a pathogenic variant is identified:

• Targeted testing for relatives: Offer genetic counseling and testing for the specific variant to first-degree relatives (parents, siblings, children) 1
• Inheritance pattern: Most familial pulmonary fibrosis follows autosomal dominant inheritance (50% transmission risk) 1
• Genetic anticipation: Progressive telomere shortening across generations can result in earlier disease onset and higher bone marrow failure risk in subsequent generations 1

Surveillance for Extrapulmonary Manifestations

Patients with short telomeres require multisystem monitoring 1, 4:

• Hematologic: Serial complete blood counts to detect cytopenias, bone marrow failure, or clonal evolution (MDS/AML risk begins in late teens) 5, 4
• Hepatic: Noninvasive liver assessment for chronic liver disease 4
• Malignancy screening:
  • Lung cancer surveillance (especially with SFTPA1/2 variants) 1
  • Head and neck squamous cell carcinoma screening 5
  • Dermatologic exams for skin cancer 5

Interpreting Variants of Uncertain Significance

TL measurement helps reclassify variants of uncertain significance (VUS) 1, 3:

• Short age-adjusted TL (<1st percentile) argues for pathogenicity of telomere gene VUS 1, 3
• TL >50th percentile makes pathogenic telomere variant less likely 1
• TL testing below the 1st percentile helped reclassify 8 of 9 VUS into actionable findings in one clinical series 3

Critical Pitfalls to Avoid

Do NOT order telomere testing for:

• Sporadic pulmonary fibrosis without suggestive extrapulmonary manifestations 1
• Routine pre-lung transplant evaluation 1
• Common variant testing (e.g., MUC5B) 1
• Unaffected relatives when proband testing was negative 1

Important caveats:

• TL measurement alone is an imprecise screening tool; clinical context and family history are essential for interpretation 1
• Different assay methods (flow-FISH vs. qPCR) may have non-equivalent age-adjusted percentile cutoffs 3
• Disease penetrance and severity are highly variable even with identified pathogenic variants 1

Disease-Modifying Therapy Considerations

Androgen therapy represents a widely applicable disease-modifying option for patients with confirmed short telomere syndrome and bone marrow manifestations 4, though specific protocols should be guided by hematology consultation.

The clinical impact is substantial: In one prospective study, TL testing altered treatment decisions in 32% of interstitial lung disease patients and 24% of bone marrow failure patients 3, 2.